Lymphoma, B-Cell News

This RSS feed URL is deprecated


This RSS feed URL is deprecated, please update. New URLs can be found in the footers at https://news.google.com/news

'Encouraging' results with JCAR017 for relapsed, refractory lymphoma - Healio



'Encouraging' results with JCAR017 for relapsed, refractory lymphoma 
Healio
High-risk patients with relapsed and refractory diffuse large B-cell lymphoma who received JCAR17 chimeric antigen receptor T-cell therapy had an overall response rate of 80% and a complete remission rate of 55%, according to results of a phase 1 trial ...

 


JCAR017 for B-Cell NHL - OncLive



JCAR017 for B-Cell NHL 
OncLive
And I think Steve's approach using Novartis tisagenlecleucel in lymphoma also kind of mirrors that where the toxicities come on a little bit later and maybe slightly less severe. But, obviously, we really need 2-year to 5-year follow-up. Follow-up is ...

 


Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma - OncLive



OncLive
 
Axi-Cel and Future of CAR T-Cell Therapy in Lymphoma 
OncLive
So, in patients with aggressive B-cell non-Hodgkin's lymphoma, when they're initially diagnosed they are typically treated with R-CHOP or a R-CHOP-like chemotherapy regimen, and that is estimated to cure about 60% of those patients. But if they relapse ...

and more » 


Would-be burglar hits partner in head with brick - FOX 13 News, Tampa Bay



FOX 13 News, Tampa Bay
 
Would-be burglar hits partner in head with brick 
FOX 13 News, Tampa Bay
Like the pirate she most admires, Jack Sparrow, Leona has been putting up a fight of her own: Last summer, she was diagnosed with B-cell lymphoma and leukemia. She's since had a tumor removed from her eye and has been undergoing chemotherapy, which has ...

and more » 


ICER report finds costs of approved CAR-T therapies align with clinical benefit - The Pharma Letter



The Pharma Letter
 
ICER report finds costs of approved CAR-T therapies align with clinical benefit 
The Pharma Letter
Both tisagenlecleucel and axicabtagene ciloleucel were evaluated for use in adults with relapsed or refractory B-cell lymphoma. Axicabtagene ciloleucel received approval for this indication in late 2017, while tisagenlecleucel is currently under US ...

 


Clinical Data for Axi-Cel in Lymphoma - OncLive



OncLive
 
Clinical Data for Axi-Cel in Lymphoma 
OncLive
To be eligible for this trial, these patients had to have refractory diffused live B-cell lymphoma, the standard B-cell lymphoma, or transformed follicular lymphoma. And we used a very stringent definition of refractoriness. These patients had to have ...

and more » 


Other Promising Strategies in CLL - OncLive



Other Promising Strategies in CLL 
OncLive
... Clinic presented their interesting study enrolling patients with relapsed/refractory CLL, as well as Richter transformation, with pembrolizumab. So, their observation is very interesting in that the CLL patient actually did not respond to the T-1 ...

 


DAAs Well Tolerated with Chemotherapy for Comorbid HCV, Non-Hodgkin's Lymphoma - MD Magazine



MD Magazine
 
DAAs Well Tolerated with Chemotherapy for Comorbid HCV, Non-Hodgkin's Lymphoma 
MD Magazine
The investigators recruited 20 consecutive HCV-positive genotype 1b-infected patients affected with diffuse large B-cell lymphoma (DLBCL; 13 male, 7 female) referred to 1 of 3 hepatology clinics for DAA treatment, from hematological treatment centers ...

 


Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers - GlobeNewswire (press release)



GlobeNewswire (press release)
 
Cellectar Initiates DLBCL Cohort in Phase 2 Trial of CLR 131 in Refractory B-Cell Hematologic Cancers 
GlobeNewswire (press release)
MADISON, Wis., Jan. 29, 2018 (GLOBE NEWSWIRE) -- Cellectar Biosciences (Nasdaq:CLRB), a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer, today announces that it ...

and more » 


Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination ... - Business Wire (press release)



Press Telegraph
 
Verastem Presents Preclinical Data at ASCO-SITC Highlighting the Synergistic Effects of Duvelisib in Combination ... 
Business Wire (press release)
BOSTON--(BUSINESS WIRE)--Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to improve the survival and quality of life of cancer patients, today announced that a poster highlighting the synergistic effects of duvelisib in ...
Oppenheimer Assigns a Buy Rating on Verastem Analyst Ratings
Verastem, Inc. - VSTM - Stock Price Today - Zacks Zacks

all 34 news articles »